Savient Pharmaceuticals (NASDAQOTH: SVNTQ ) , already up 106% in August, has doubled again in September. What is fueling this run?
After getting pushed to the brink by creditor Tang Capital, Savient won in court against accusations of insolvency. Shares have since bounced back to where they were pre-brouhaha. Does this make the company a buy, though? Not unless you think sales of drug Krystexxa will increase significantly, as Savient is currently cutting its way to breakeven.
Fool.com analyst David Williamson refrains from investing in biotechs that stumble out of the gate, even if happy endings do occasionally result -- for instance, in the case of Human Genome Sciences' GlaxoSmithKline (NYSE: GSK ) lifeboat. Far more often the result is continued wealth destruction, case in point being Dendreon's (NASDAQOTH: DNDNQ ) recent poaching of Savient's former CEO. Dendreon shares are now worth roughly one-tenth of their high two years ago.
See more in the following video.
When it comes to a do-or-die business, the biotech industry takes the cake. Arena Pharmaceuticals is another recent success story in the industry after gaining FDA approval for its innovative obesity drug. However, while the future looks bright, there are still plenty of obstacles ahead for Arena. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for all who sign up. To learn more and get started, click here now.